title: Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
abstract: OBJECTIVE
  The ability to predict response to chemoradiotherapy before the treatment may allow protecting poorly responding patients from the side effects of neoadjuvant treatment. Several molecular markers have been proposed to radio and chemosensitivity of rectal cancer. In this study, from pre-irradiation tumor biopsies, a novel and promising candidate factor survivin, and p53 and Ki-67 were assessed as predictors of response to preoperative chemoradiotherapy.
  
  
  METHODS
  Expression of each marker was evaluated by immunohistochemistry on pretreatment biopsies from 37 patients having rectal cancer treated with preoperative chemoradiotherapy and curative surgery. Treatment response was assessed histopathologically in the resected surgical specimen.
  
  
  RESULTS
  There was no correlation between expression of p53, Ki-67, and survivin with response to preoperative chemoradiotherapy and prognosis.
  
  
  CONCLUSIONS
  Our data suggest that these molecular markers are not helpful to identify patients who would have benefit from neoadjuvant treatment of rectal cancer. Further investigations are necessary to select patients for preoperative treatment based on analysis of the preoperative biopsies.
authors.affiliation: Department of Surgery, School of Medicine, Dokuz Eylul University, Izmir, Inciralti 35340, Turkey. cem.terzi@deu.edu.tr
authors.forename: Cem
authors.initials: C
authors.lastname: Terzi
authors.forename: Aras Emre
authors.initials: AE
authors.lastname: Canda
authors.forename: Ozgul
authors.initials: O
authors.lastname: Sagol
authors.forename: Koray
authors.initials: K
authors.lastname: Atila
authors.forename: Devrim
authors.initials: D
authors.lastname: Sonmez
authors.forename: Mehmet
authors.initials: M
authors.lastname: Fuzun
authors.forename: Ilknur B
authors.initials: IB
authors.lastname: Gorken
authors.forename: Ilhan
authors.initials: I
authors.lastname: Oztop
authors.forename: Funda
authors.initials: F
authors.lastname: Obuz
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D013505:Digestive System Surgical Procedures; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D019394:Ki-67 Antigen / Q000032:analysis*; D008297:Male; D008869:Microtubule-Associated Proteins / Q000032:analysis*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000032:analysis*; D018579:Patient Selection; D018714:Radiotherapy, Adjuvant; D012004:Rectal Neoplasms / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D012189:Retrospective Studies; D000077022:Survivin; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*